Review





Similar Products

94
Sino Biological pcmv3egfr flag
Pcmv3egfr Flag, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr/Human+EGFR%2FHER1+Gene+ORF+cDNA+clone+expression+plasmid%2C+C-Flag+tag/10__1038_slash_s41467___026___79134___z-410-9-10
Average 94 stars, based on 1 article reviews
pcmv3egfr flag - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

92
BPS Bioscience recombinant egfr protein
High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant <t>EGFR</t> signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: <t>L858R/T790M;</t> LTC: <t>L858R/T790M/C797S.</t> #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels
Recombinant Egfr Protein, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr/EGFR%2C+His-tag%2C+GST-tag+Recombinant/pmc13756994-93-4-15
Average 92 stars, based on 1 article reviews
recombinant egfr protein - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

95
BPS Bioscience kinase glo max luminescent assay kit
High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant <t>EGFR</t> signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: <t>L858R/T790M;</t> LTC: <t>L858R/T790M/C797S.</t> #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels
Kinase Glo Max Luminescent Assay Kit, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr/EGFR+Kinase+Assay+Kit/pmc13752819-417-22-27
Average 95 stars, based on 1 article reviews
kinase glo max luminescent assay kit - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

98
Addgene inc egfr
High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant <t>EGFR</t> signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: <t>L858R/T790M;</t> LTC: <t>L858R/T790M/C797S.</t> #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels
Egfr, supplied by Addgene inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr/psPAX2+(Plasmid+%2312260)/pm43001588-266-11-19
Average 98 stars, based on 1 article reviews
egfr - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

95
BPS Bioscience egfr assay kit
High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant <t>EGFR</t> signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: <t>L858R/T790M;</t> LTC: <t>L858R/T790M/C797S.</t> #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels
Egfr Assay Kit, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr/EGFR+Kinase+Assay+Kit/pmc13764303-230-7-10
Average 95 stars, based on 1 article reviews
egfr assay kit - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
BPS Bioscience egfr kinase assay kit
High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant <t>EGFR</t> signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: <t>L858R/T790M;</t> LTC: <t>L858R/T790M/C797S.</t> #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels
Egfr Kinase Assay Kit, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr/EGFR+Kinase+Assay+Kit/pm42998399-331-26-30
Average 95 stars, based on 1 article reviews
egfr kinase assay kit - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc rabbit anti phospho egfr
High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant <t>EGFR</t> signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: <t>L858R/T790M;</t> LTC: <t>L858R/T790M/C797S.</t> #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels
Rabbit Anti Phospho Egfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr/Phospho-EGF+Receptor+(Tyr1068)+Antibody/pm42986876-140-48-50
Average 96 stars, based on 1 article reviews
rabbit anti phospho egfr - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
Proteintech anti egfr
High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant <t>EGFR</t> signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: <t>L858R/T790M;</t> LTC: <t>L858R/T790M/C797S.</t> #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels
Anti Egfr, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr/EGFR-Specific+Antibody/pm42988846-151-3-5
Average 94 stars, based on 1 article reviews
anti egfr - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
R&D Systems human egfr alexa fluor 405 conjugated antibody
High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant <t>EGFR</t> signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: <t>L858R/T790M;</t> LTC: <t>L858R/T790M/C797S.</t> #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels
Human Egfr Alexa Fluor 405 Conjugated Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr/Human+EGFR+(Research+Grade+Cetuximab+Biosimilar)+Alexa+Fluor%C2%AE+405-conjugated+Antibody/pm42977121-59-51-59
Average 94 stars, based on 1 article reviews
human egfr alexa fluor 405 conjugated antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

95
MedChemExpress generation irreversible egfr tki afatinib
High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant <t>EGFR</t> signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: <t>L858R/T790M;</t> LTC: <t>L858R/T790M/C797S.</t> #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels
Generation Irreversible Egfr Tki Afatinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr/Afatinib/pm42974657-51-2-7
Average 95 stars, based on 1 article reviews
generation irreversible egfr tki afatinib - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant EGFR signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: L858R/T790M; LTC: L858R/T790M/C797S. #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels

Journal: Journal of Biomedical Science

Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

doi: 10.1186/s12929-026-01297-0

Figure Lengend Snippet: High-throughput screening identifies abemaciclib as a selective suppressor of osimertinib-resistant mutant EGFR signaling. A Schematic overview of the drug-screening protocol for the EGFR-LTC inhibitor abemaciclib. B A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation of Ba/F3 cells expressing different mutant types of EGFR with or without IL-3. 1st: First-round drug selection; 2nd: second-round drug selection; 3rd: third-round drug selection. LT: L858R/T790M; LTC: L858R/T790M/C797S. #: The drug was ineffective; *: the drug did not dissolve; NA: not applicable. C A high-throughput screening assay of ~125,000 compounds was performed to measure cell proliferation in EGFR-TKI resistant Ba/F3 cells expressing mutant EGFR variants. D Cells were treated with abemaciclib at the indicated concentration for 72 hours. Cell viability was analyzed using the MTS assay, and the IC50 values were comparable (on the right). The error bars represent the means ± SDs; n =3. Ba/F3 EGFR-LTC ( E ) or Ba/F3 EGFR DTC cells ( F ) were treated with abemaciclib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. G EGFR-LTC cells were treated with brigatinib in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. EGFR-LT cells were treated with paclitaxel ( H ), cisplatin ( I ), and osimertinib ( J ) in the absence or presence of IL-3 at the indicated concentration for 72 hours, and cell viability was analyzed using the MTS assay. K The proportions of H1975-LTC cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. L Apoptosis assays were performed in H1975-LTC cells treated with the pancaspase inhibitor Z-VAD-FMK at the indicated concentration for 72 hours. M H1975-LTC cells were treated with the indicated concentration of abemaciclib for 48 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels

Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

Techniques: High Throughput Screening Assay, Mutagenesis, Drug discovery, Expressing, Selection, Concentration Assay, MTS Assay, Control, Western Blot, HTS Assay

Abemaciclib suppresses phosphorylation of osimertinib-resistant EGFR triple mutants in vitro. Effect of abemaciclib on phosphorylated EGFR levels. A Immunoprecipitation (IP) and Western blotting were performed in H1975-LTC cells treated with abemaciclib for 6 hours, and the levels of phosphorylated EGFR were analyzed. β-actin served as a loading control. Effects of abemaciclib or osimertinib on phosphorylated EGFR levels. After 6 hours of abemaciclib incubation, phosphorylated EGFR levels were determined in Ba/F3-DT ( B ), Ba/F3-DTC ( C ), Ba/F3-LTC ( D ), H1975-LT ( E ), H1975-LTC ( F ) cells and phosphorylated S6 levels were determined in H1975-LTC ( F ) by Western blotting. Quantitative plots are shown on the right ( C and D ) or below ( F ) and each experiment was performed in three independent replicates, and the values for each treatment group were normalized to the corresponding control within the same experiment. Each treatment group was compared with the control using a two-tailed one-sample Student‘s t-test. Multiple comparisons were accounted for using the Benjamini-Hochberg (BH) false discovery rate (FDR) correction and an adjusted P value<0.05 was considered statistically significant. G The levels of phosphorylated EGFR were examined in BaF3-Del 19, BaF3-DT, BaF3-DTC, BaF3-L858R, BaF3-LT, BaF3-LTC cells by Western blotting, and quantitative plots are shown below. The error bars represent the means ± SDs; n =3

Journal: Journal of Biomedical Science

Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

doi: 10.1186/s12929-026-01297-0

Figure Lengend Snippet: Abemaciclib suppresses phosphorylation of osimertinib-resistant EGFR triple mutants in vitro. Effect of abemaciclib on phosphorylated EGFR levels. A Immunoprecipitation (IP) and Western blotting were performed in H1975-LTC cells treated with abemaciclib for 6 hours, and the levels of phosphorylated EGFR were analyzed. β-actin served as a loading control. Effects of abemaciclib or osimertinib on phosphorylated EGFR levels. After 6 hours of abemaciclib incubation, phosphorylated EGFR levels were determined in Ba/F3-DT ( B ), Ba/F3-DTC ( C ), Ba/F3-LTC ( D ), H1975-LT ( E ), H1975-LTC ( F ) cells and phosphorylated S6 levels were determined in H1975-LTC ( F ) by Western blotting. Quantitative plots are shown on the right ( C and D ) or below ( F ) and each experiment was performed in three independent replicates, and the values for each treatment group were normalized to the corresponding control within the same experiment. Each treatment group was compared with the control using a two-tailed one-sample Student‘s t-test. Multiple comparisons were accounted for using the Benjamini-Hochberg (BH) false discovery rate (FDR) correction and an adjusted P value<0.05 was considered statistically significant. G The levels of phosphorylated EGFR were examined in BaF3-Del 19, BaF3-DT, BaF3-DTC, BaF3-L858R, BaF3-LT, BaF3-LTC cells by Western blotting, and quantitative plots are shown below. The error bars represent the means ± SDs; n =3

Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

Techniques: Phospho-proteomics, In Vitro, Immunoprecipitation, Western Blot, Control, Incubation, Two Tailed Test

Abemaciclib selectively inhibits mutant EGFR and directly engages resistant EGFR variants. A An in vitro kinase assay was performed to measure the kinase activity of EGFR-WT and EGFR-LTC proteins treated with abemaciclib at the indicated concentrations. EGFR-LTC kinase activity was determined in vitro to measure the kinase activity of EGFR-LTC protein after treatment with abemaciclib, along with a relatively high concentration of ATP ( B ) or substrate ( C ). The IC50 values are presented below the chart. D An in vitro kinase assay was conducted to measure the kinase activity of the WT, L858R, LT and LTC-EGFR proteins treated with abemaciclib at the indicated concentrations. Effect of abemaciclib on phosphorylated EGFR levels in cells treated with or without EGF. The levels of phosphorylated EGFR were examined in H460 ( E ), Hop92 ( F ), H1975-LT ( G ) and H1975-LTC ( H ) cells by Western blotting. Quantitative plots are shown below. Each treatment group was compared with the EGF ligand stimulation group using a two-tailed one-sample Student's t-test. Multiple comparisons were accounted for using the Benjamini-Hochberg (BH) false discovery rate (FDR) correction and an adjusted P value < 0.05 was considered statistically significant. GAPDH served as a loading control in all the Western blotting panels. I A cellular thermal shift assay (CETSA) was performed in H1975-35 cells. H1975-35 cells were treated with DMSO or abemaciclib and subjected to the indicated temperature gradient (0–64°C). Cell lysates were analyzed by Western blotting for EGFR, CDK4, and β-actin. Band intensities were quantified by densitometry and normalized to the 0 °C condition. β-actin was used as a loading control. The binding mode of abemaciclib complexed with the EGFR L858R/T790M (PDB ID: 3IKA) ( J ) and EGFR L858R/T790M/C797S (PDB ID: 6LUB) structures ( K ) was analyzed by molecular docking. A summary table is shown ( L ). M Phosphokinase array analysis (#ARY003B; R&D Systems) was performed after treatment with abemaciclib. The bar graph showed differences of more than 2-fold between the abemaciclib-treated and control groups

Journal: Journal of Biomedical Science

Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

doi: 10.1186/s12929-026-01297-0

Figure Lengend Snippet: Abemaciclib selectively inhibits mutant EGFR and directly engages resistant EGFR variants. A An in vitro kinase assay was performed to measure the kinase activity of EGFR-WT and EGFR-LTC proteins treated with abemaciclib at the indicated concentrations. EGFR-LTC kinase activity was determined in vitro to measure the kinase activity of EGFR-LTC protein after treatment with abemaciclib, along with a relatively high concentration of ATP ( B ) or substrate ( C ). The IC50 values are presented below the chart. D An in vitro kinase assay was conducted to measure the kinase activity of the WT, L858R, LT and LTC-EGFR proteins treated with abemaciclib at the indicated concentrations. Effect of abemaciclib on phosphorylated EGFR levels in cells treated with or without EGF. The levels of phosphorylated EGFR were examined in H460 ( E ), Hop92 ( F ), H1975-LT ( G ) and H1975-LTC ( H ) cells by Western blotting. Quantitative plots are shown below. Each treatment group was compared with the EGF ligand stimulation group using a two-tailed one-sample Student's t-test. Multiple comparisons were accounted for using the Benjamini-Hochberg (BH) false discovery rate (FDR) correction and an adjusted P value < 0.05 was considered statistically significant. GAPDH served as a loading control in all the Western blotting panels. I A cellular thermal shift assay (CETSA) was performed in H1975-35 cells. H1975-35 cells were treated with DMSO or abemaciclib and subjected to the indicated temperature gradient (0–64°C). Cell lysates were analyzed by Western blotting for EGFR, CDK4, and β-actin. Band intensities were quantified by densitometry and normalized to the 0 °C condition. β-actin was used as a loading control. The binding mode of abemaciclib complexed with the EGFR L858R/T790M (PDB ID: 3IKA) ( J ) and EGFR L858R/T790M/C797S (PDB ID: 6LUB) structures ( K ) was analyzed by molecular docking. A summary table is shown ( L ). M Phosphokinase array analysis (#ARY003B; R&D Systems) was performed after treatment with abemaciclib. The bar graph showed differences of more than 2-fold between the abemaciclib-treated and control groups

Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

Techniques: Mutagenesis, In Vitro, Kinase Assay, Activity Assay, Concentration Assay, Western Blot, Two Tailed Test, Control, Thermal Shift Assay, Binding Assay, Docking Assay, Analysis

Abemaciclib suppresses tumor growth in xenograft models harboring EGFR L858R/T790M/C797S mutations. A schematic representation of the experimental procedure of the animal model is shown at the top. ( A – E ) Effect of oral gavage of abemaciclib or osimertinib on tumor growth. The tumor volume was measured as described in the Materials and Methods (n = 6 mice per group). ( F–G ) After the in vivo assay was performed, the mice were sacrificed, and the net tumor weights were measured. The data are presented as the means ± SEMs. * P < 0.05, ** P < 0.01, and *** P < 0.001. H Abemaciclib decreased p-EGFR levels in H1975-LTC xenograft tumors. The protein extracts from the tumor sections were subjected to Western blotting. I Effects of abemaciclib or osimertinib oral gavage on mouse body weight. J Abemaciclib decreased p-EGFR levels in H1975-EGFR-LTC xenograft tumors. The protein extracts from the tumor sections were subjected to Western blotting

Journal: Journal of Biomedical Science

Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

doi: 10.1186/s12929-026-01297-0

Figure Lengend Snippet: Abemaciclib suppresses tumor growth in xenograft models harboring EGFR L858R/T790M/C797S mutations. A schematic representation of the experimental procedure of the animal model is shown at the top. ( A – E ) Effect of oral gavage of abemaciclib or osimertinib on tumor growth. The tumor volume was measured as described in the Materials and Methods (n = 6 mice per group). ( F–G ) After the in vivo assay was performed, the mice were sacrificed, and the net tumor weights were measured. The data are presented as the means ± SEMs. * P < 0.05, ** P < 0.01, and *** P < 0.001. H Abemaciclib decreased p-EGFR levels in H1975-LTC xenograft tumors. The protein extracts from the tumor sections were subjected to Western blotting. I Effects of abemaciclib or osimertinib oral gavage on mouse body weight. J Abemaciclib decreased p-EGFR levels in H1975-EGFR-LTC xenograft tumors. The protein extracts from the tumor sections were subjected to Western blotting

Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

Techniques: Xenograft Assay, Animal Model, In Vivo, Western Blot, Two Tailed Test

Abemaciclib inhibits mutant EGFR signaling and induces apoptosis in CRISPR-engineered EGFR C797S isogenic models. H1975 and isogenic cells (H1975-12 and H1975-35) were treated with osimertinib ( A ) or abemaciclib ( B ) at the indicated concentrations for 72 hours, and cell viability was analyzed using the MTS assay. Effects of abemaciclib or osimertinib on phosphorylated EGFR levels. The levels of phosphorylated EGFR were examined in H1975-12 ( C ) and H1975-35 ( D ) cells by Western blotting and were quantified using ImageJ software. GAPDH served as a loading control. The proportions of H1975-12 ( E ) and H1975-35 ( F ) cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. H1975-12 ( G ) and H1975-35 ( H ) cells were treated with the indicated concentrations of abemaciclib or osimertinib for 72 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels

Journal: Journal of Biomedical Science

Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

doi: 10.1186/s12929-026-01297-0

Figure Lengend Snippet: Abemaciclib inhibits mutant EGFR signaling and induces apoptosis in CRISPR-engineered EGFR C797S isogenic models. H1975 and isogenic cells (H1975-12 and H1975-35) were treated with osimertinib ( A ) or abemaciclib ( B ) at the indicated concentrations for 72 hours, and cell viability was analyzed using the MTS assay. Effects of abemaciclib or osimertinib on phosphorylated EGFR levels. The levels of phosphorylated EGFR were examined in H1975-12 ( C ) and H1975-35 ( D ) cells by Western blotting and were quantified using ImageJ software. GAPDH served as a loading control. The proportions of H1975-12 ( E ) and H1975-35 ( F ) cells in the sub-G1 phase were determined after abemaciclib or osimertinib treatment. H1975-12 ( G ) and H1975-35 ( H ) cells were treated with the indicated concentrations of abemaciclib or osimertinib for 72 hours, after which the cell lysates were harvested. Protein extracts were immunoblotted with the indicated antibodies. β-Actin served as a loading control in all the Western blotting panels

Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

Techniques: Mutagenesis, CRISPR, MTS Assay, Western Blot, Software, Control

Abemaciclib demonstrates potent antitumor activity in EGFR C797S isogenic xenograft models. A schematic representation of the experimental procedure of the animal model is shown at the top. ( A – H ) Effect of oral gavage of abemaciclib or osimertinib on the tumor growth of the H1975 isogenic line. The tumor volume was measured as described in the Materials and Methods (n=6 mice per group). I After the in vivo assay was performed, the mice were sacrificed, and the net tumor weights were measured. The data are presented as the means ± SEMs. * P < 0.05, ** P < 0.01, and *** P < 0.001. ( J – K ) Abemaciclib decreased p-EGFR levels in H1975-LTC isogenic xenograft tumors. The protein extracts from the tumor sections were subjected to Western blotting. L Effects of oral gavage of abemaciclib and osimertinib on mouse body weight

Journal: Journal of Biomedical Science

Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

doi: 10.1186/s12929-026-01297-0

Figure Lengend Snippet: Abemaciclib demonstrates potent antitumor activity in EGFR C797S isogenic xenograft models. A schematic representation of the experimental procedure of the animal model is shown at the top. ( A – H ) Effect of oral gavage of abemaciclib or osimertinib on the tumor growth of the H1975 isogenic line. The tumor volume was measured as described in the Materials and Methods (n=6 mice per group). I After the in vivo assay was performed, the mice were sacrificed, and the net tumor weights were measured. The data are presented as the means ± SEMs. * P < 0.05, ** P < 0.01, and *** P < 0.001. ( J – K ) Abemaciclib decreased p-EGFR levels in H1975-LTC isogenic xenograft tumors. The protein extracts from the tumor sections were subjected to Western blotting. L Effects of oral gavage of abemaciclib and osimertinib on mouse body weight

Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

Techniques: Activity Assay, Xenograft Assay, Animal Model, In Vivo, Western Blot

Abemaciclib inhibits tumor growth in a PDX model harboring EGFR-DTC mutations both in vitro and in vivo. Sequencing analysis of CLH206 cells, which express the EGFR Del19/T790M (+/ − : 40/60)/C797S (+/−: 60/40) mutant ( A ) or VGHT11 cells, which express the EGFR Del19/T790M (+/ − : 50/50)/C797S (+/ − : 30/70) mutant ( B ). CLH206 cells and VGHT11 were treated with osimertinib ( C ) or abemaciclib ( D ) at the indicated concentrations for 72 hours, and cell viability was analyzed using the MTS assay. E Effects of abemaciclib or osimertinib on phosphorylated EGFR levels in CLH206 cells, as determined by Western blotting. GAPDH served as a loading control. F A schematic representation of the experimental procedure of the animal model. ( G – K ) Effect of oral gavage of abemaciclib or osimertinib on the growth of CLH206 tumors. The tumor volume was measured as described in the Materials and Methods (n = 8 mice per group). ( L – M ) After the in vivo assay was performed, the mice were sacrificed, and the net tumor weights were measured. The data are presented as the means ± SEMs. * P < 0.05, ** P < 0.01, and *** P < 0.001. N Effects of oral gavage of abemaciclib or osimertinib on the body weights of the mice. The levels of ALT ( O ), AST ( P ), BUN ( Q ), and CRE ( R ) in CLH206 tumor-bearing mice treated with abemaciclib or osimertinib, excluding those in mice with hemolyzed blood, were evaluated

Journal: Journal of Biomedical Science

Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

doi: 10.1186/s12929-026-01297-0

Figure Lengend Snippet: Abemaciclib inhibits tumor growth in a PDX model harboring EGFR-DTC mutations both in vitro and in vivo. Sequencing analysis of CLH206 cells, which express the EGFR Del19/T790M (+/ − : 40/60)/C797S (+/−: 60/40) mutant ( A ) or VGHT11 cells, which express the EGFR Del19/T790M (+/ − : 50/50)/C797S (+/ − : 30/70) mutant ( B ). CLH206 cells and VGHT11 were treated with osimertinib ( C ) or abemaciclib ( D ) at the indicated concentrations for 72 hours, and cell viability was analyzed using the MTS assay. E Effects of abemaciclib or osimertinib on phosphorylated EGFR levels in CLH206 cells, as determined by Western blotting. GAPDH served as a loading control. F A schematic representation of the experimental procedure of the animal model. ( G – K ) Effect of oral gavage of abemaciclib or osimertinib on the growth of CLH206 tumors. The tumor volume was measured as described in the Materials and Methods (n = 8 mice per group). ( L – M ) After the in vivo assay was performed, the mice were sacrificed, and the net tumor weights were measured. The data are presented as the means ± SEMs. * P < 0.05, ** P < 0.01, and *** P < 0.001. N Effects of oral gavage of abemaciclib or osimertinib on the body weights of the mice. The levels of ALT ( O ), AST ( P ), BUN ( Q ), and CRE ( R ) in CLH206 tumor-bearing mice treated with abemaciclib or osimertinib, excluding those in mice with hemolyzed blood, were evaluated

Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

Techniques: In Vitro, In Vivo, Sequencing, Analysis, Mutagenesis, MTS Assay, Western Blot, Control, Animal Model

Proposed model of mutation-selective suppression of C797S-mutant EGFR by abemaciclib. Acquisition of the EGFR C797S mutation confers resistance to osimertinib and sustains oncogenic EGFR signaling. Through high-throughput screening, abemaciclib was identified as a potent suppressor of C797S-containing EGFR variants. Biochemical assays, CETSA analyses, and molecular docking studies support direct engagement of mutant EGFR by abemaciclib. Inhibition of mutant EGFR signaling results in reduced EGFR phosphorylation, induction of apoptotic cell death, and suppression of tumor growth in CRISPR-engineered and patient-derived xenograft models of osimertinib-resistant EGFR-mutant NSCLC. This schematic summarizes the proposed mechanism and therapeutic implications of abemaciclib in overcoming EGFR C797S-mediated osimertinib resistance. The model is based on experimental observations and does not represent an experimentally resolved binding structure

Journal: Journal of Biomedical Science

Article Title: Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma

doi: 10.1186/s12929-026-01297-0

Figure Lengend Snippet: Proposed model of mutation-selective suppression of C797S-mutant EGFR by abemaciclib. Acquisition of the EGFR C797S mutation confers resistance to osimertinib and sustains oncogenic EGFR signaling. Through high-throughput screening, abemaciclib was identified as a potent suppressor of C797S-containing EGFR variants. Biochemical assays, CETSA analyses, and molecular docking studies support direct engagement of mutant EGFR by abemaciclib. Inhibition of mutant EGFR signaling results in reduced EGFR phosphorylation, induction of apoptotic cell death, and suppression of tumor growth in CRISPR-engineered and patient-derived xenograft models of osimertinib-resistant EGFR-mutant NSCLC. This schematic summarizes the proposed mechanism and therapeutic implications of abemaciclib in overcoming EGFR C797S-mediated osimertinib resistance. The model is based on experimental observations and does not represent an experimentally resolved binding structure

Article Snippet: Briefly, 500 ng of recombinant EGFR protein (EGFR WT, Cat. 40187; EGFR L858R/T790M/C797S, Cat. 40351, BPS, Bioscience), 5 μg of substrate (poly (Glu-Tyr), P 0275, Sigma) and 250 picomole of ATP in EGRF kinase buffer (50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35) supplemented with vehicle or inhibitors were added in a total volume of 25 μl at room temperature for one hour.

Techniques: Mutagenesis, High Throughput Screening Assay, Docking Assay, Inhibition, Phospho-proteomics, CRISPR, Derivative Assay, Xenograft Assay, Binding Assay